Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma.

Overview of attention for article published in JCO Precision Oncology, February 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)

Mentioned by

twitter: 6 X users

Readers on

mendeley: 27 Mendeley

So far, Altmetric has seen 7 X posts from 6 X users, with an upper bound of 71,183 followers.

#JCOPO | Respuesta a #dabrafenib + #trametinib después del fracaso del tratamiento con inhibidor de #BRAF para #Glioblastoma. Artículo: https://t.co/CS8Jx2OhEK https://t.co/H4iHEugqG5

RT @delaFuenteNOnc: Proud to share the work of our resident Dr. Marina Kushnirsky and our neuro-oncology team at @SylvesterCancer @UMiamiNe…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 3 additional X posts.